Finance

Beta
Lists
CIPLA:NSE
Cipla Ltd
₹ १,३८२.६०
-०.४९%
(-६.८०) 1D
जुन १५, १२:२२:४९ GMT+५:३०  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for CIPLA...
Open
₹ १,३९६.७०
High
₹ १,३९७.९०
Low
₹ १,३७४.५०
Mkt. cap
११.१८ खरब
Avg. vol.
१८.७१ लाख
Volume
७.९१ लाख
Dividend
०.९४%
Quarterly dividend
₹ ३.२५
Ex-dividend date
२०२६ जुन ५
P/E ratio
२८.८१
52-wk high
₹ १,६७३.००
52-wk low
₹ १,१६५.७०
EPS
₹ ४८.००
Shares outstanding
८०.५७ करोड
No. of employees
३१ हजार
Open
₹ १,३९६.७०
High
₹ १,३९७.९०
Low
₹ १,३७४.५०
Mkt. cap
११.१८ खरब
Avg. vol.
१८.७१ लाख
Volume
७.९१ लाख
Dividend
०.९४%
Quarterly dividend
₹ ३.२५
Ex-dividend date
२०२६ जुन ५
P/E ratio
२८.८१
52-wk high
₹ १,६७३.००
52-wk low
₹ १,१६५.७०
EPS
₹ ४८.००
Shares outstanding
८०.५७ करोड
No. of employees
३१ हजार
Analyst outlook
Analyst Ratings
Based on 3 analysts giving stock ratings to CIPLA in the past 3 months
Hold
Buy
1
Hold
1
Sell
1
12 month forecast
Based on 3 Wall Street analysts offering 12 month price targets for CIPLA in the last 3 months.
Highest
Current ₹ १,३८२.६०
₹ १,५५०.०० (+१२.११%)
Average
₹ १,४०३.३३ (+१.५०%)
Lowest
₹ १,१२०.०० (-१८.९९%)
News stories
From sources across the web
Investing.com
Investing.com
·
१० मिनेट पहिले
S&P 500 Earnings: Can Banks Reignite Momentum as Reporting Season Begins?
MarketBeat
MarketBeat
·
१६ मिनेट पहिले
FTAI Aviation Ltd. (NASDAQ:FTAI) Given Consensus Recommendation of "Moderate Buy" by Analysts
TradingView
TradingView
·
३५ मिनेट पहिले
SPX: S&P 500 Futures Soar Over 1% as Traders Cheer US-Iran Peace Deal
Investor's Business Daily
Investor's Business Daily
·
३ घण्टा पहिले
Dow Jones Futures Rise, Oil Prices Dive As Trump Announces Iran Deal; SpaceX's Next Test
Profile
Cipla Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. Cipla primarily focuses on developing medication to treat respiratory disease, cardiovascular disease, arthritis, diabetes, depression, paediatric and various other medical conditions. Cipla has 47 manufacturing locations across the world and sells its products in 86 countries. It is the third-largest drug producer in India. Wikipedia
About Cipla Ltd
CEOUmang Vohra
Employees३१.४ हजार
Founded१९३५
Headquartersमुम्बई, महाराष्ट्र, भारत
Sector-
Websitecipla.com
Last report
२०२६ मे १३
Fiscal period
Q4 2026
EPS / Est. (INR)
₹ ६.८६ / ₹ ९.६७
-२९.०७%miss
Revenue / Est. (INR)
६५.८० अरब / ६७.१४ अरब
-१.९९%miss
Fiscal Q4 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in INR
२०२५ जुन
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
Revenue
६८.३७ अरब
७४.४७ अरब
६९.६३ अरब
६५.८० अरब
Cost of goods sold
२१.७१ अरब
२४.९८ अरब
२६.३२ अरब
२५.१० अरब
Cost of revenue
२१.७१ अरब
२४.९८ अरब
२६.३२ अरब
२५.१० अरब
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
१३.१२ अरब
१३.१५ अरब
१३.२५ अरब
२८.२३ अरब
Operating expense
३१.४१ अरब
३३.५२ अरब
३३.५४ अरब
३३.३० अरब
Total operating expenses
५३.१२ अरब
५८.५० अरब
५९.८६ अरब
५८.३९ अरब
Operating income
१५.२५ अरब
१५.९८ अरब
९.७७ अरब
७.४१ अरब
Other non operating income
२.५९ अरब
२.६९ अरब
२.०६ अरब
-५.३५ अरब
EBT including unusual items
१७.६९ अरब
१८.५४ अरब
८.९३ अरब
६.९९ अरब
EBT excluding unusual items
१७.६९ अरब
१८.५४ अरब
११.६९ अरब
४.५१ अरब
Income tax expense
४.७८ अरब
५.०० अरब
२.१९ अरब
१.५७ अरब
Effective tax rate
२७.०१%
२७.००%
२४.४८%
२२.४४%
Other operating expenses
१५.७६ अरब
१७.४० अरब
१७.५१ अरब
२.५१ अरब
Net income
१२.९८ अरब
१३.५१ अरब
६.७६ अरब
५.५५ अरब
Net profit margin
१८.९८%
१८.१४%
९.७१%
८.४३%
Earnings per share
१६.०६
१६.७२
१०.९४
६.८६
Interest and investment income
-
-
-
२.०७ अरब
Interest expense
-१४.०५ करोड
-१३.१८ करोड
-१४.०३ करोड
-६.९७ करोड
Net interest expenses
-१४.०५ करोड
-१३.१८ करोड
-१४.०३ करोड
२.०० अरब
Depreciation and amortization charges
२.५३ अरब
२.९७ अरब
२.७८ अरब
२.५६ अरब
EBITDA
१७.४९ अरब
१८.७३ अरब
१२.०० अरब
९.८२ अरब
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer